Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
European Organisation for Research and Treatment of Cancer - EORTC
EBMT Solid Tumors Working Party
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: October 11, 2001
Last updated: September 16, 2013
Last verified: June 2007

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplant may allow the doctors to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which combination chemotherapy regimen given before peripheral stem cell transplant is more effective in treating relapsed Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy followed by peripheral stem cell transplant to see how well they work in treating patients with relapsed Hodgkin's lymphoma.

Condition Intervention Phase
Biological: filgrastim
Drug: carmustine
Drug: cisplatin
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: melphalan
Drug: methotrexate
Drug: vincristine sulfate
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Efficacy at 3 months [ Designated as safety issue: No ]
  • Toxicity at 3 months [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Complete remission at 3 months [ Designated as safety issue: No ]
  • Relapse-free survival at 3 months [ Designated as safety issue: No ]
  • Overall survival at 3 months [ Designated as safety issue: No ]

Estimated Enrollment: 220
Study Start Date: July 2001
Detailed Description:


  • Compare the efficacy of induction chemotherapy followed by combination chemotherapy and autologous peripheral blood stem cell transplantation with or without high-dose sequential chemotherapy in terms of freedom from treatment failure in patients with relapsed Hodgkin's lymphoma.
  • Compare the toxicity of these regimens in these patients.
  • Compare the complete remission/unconfirmed complete remission rate at 3 months, relapse-free survival, and overall survival of patients treated with these regimens.
  • Compare the frequency of severe toxic effects and secondary neoplasia in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, type of relapse (early first relapse [remission duration 3-12 months] vs late first relapse [remission duration more than 12 months] vs second relapse without prior high-dose chemotherapy salvage [remission duration after salvage at least 3 months]), disease status at relapse (stage I or II vs stage III or IV), age (18 to 49 vs 50 to 60), and response after 2 courses of study induction chemotherapy (complete remission vs partial remission vs no change).

All patients receive induction chemotherapy comprising dexamethasone IV over 30 minutes on days 1-4 and 15-18, cisplatin IV continuously over 24 hours on days 1 and 15, cytarabine IV over 3 hours every 12 hours on days 2 and 16, and filgrastim (G-CSF) subcutaneously (SC) once daily on days 5-12 and days 19-26. Patients with complete remission (CR), unconfirmed CR, partial remission, or no change are randomized to one of two treatment arms.

  • Arm I: Patients receive BEAM chemotherapy comprising carmustine IV over 30 minutes and melphalan IV over 30 minutes on day 37 and etoposide IV over 30 minutes every 12 hours and cytarabine IV over 30 minutes every 12 hours on days 37-40. Patients also receive G-CSF SC twice daily beginning on day 41 and continuing until blood counts recover. Autologous peripheral blood stem cells (PBSCs) are reinfused on day 42.
  • Arm II: Patients receive high-dose cyclophosphamide IV over 8 hours on day 37, high-dose methotrexate IV over 6 hours and high-dose vincristine IV on day 51, and high-dose etoposide IV over 8 hours on days 58-61. Patients then receive BEAM chemotherapy comprising carmustine IV over 30 minutes and melphalan IV over 30 minutes on day 80 and etoposide IV over 30 minutes every 12 hours and cytarabine IV over 30 minutes every 12 hours on days 80-83. Patients also receive G-CSF SC once on days 38 and 62 and twice daily beginning on day 84 and continuing until blood counts recover. Autologous PBSCs are reinfused on day 85.

Patients with residual lymphoma at 100 days after completion of BEAM chemotherapy may receive radiotherapy.

Patients are followed at 100 days after PBSC transplantation, every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A minimum of 220 patients (110 per treatment arm) will be accrued for this study within 5 years.


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed Hodgkin's lymphoma
  • Early or late first relapse

    • Complete or partial remission for at least 3 months after completion of prior COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy regimen with or without radiotherapy
    • No prior salvage therapy OR
  • Second relapse

    • Any prior salvage therapy
    • No prior high-dose chemotherapy



  • 18 to 60

Performance status:

  • Karnofsky 70-100% OR
  • ECOG 0-2

Life expectancy:

  • More than 3 months with treatment


  • Absolute neutrophil count at least 2,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Not specified


  • Creatinine clearance at least 60 mL/min


  • No uncontrolled hypertension (diastolic blood pressure greater than 115 mm Hg)
  • No unstable angina
  • No New York Heart Association class III or IV heart disease (congestive heart failure)
  • No myocardial infarction within the past 6 months
  • No uncontrolled atrial or ventricular cardiac arrhythmias


  • No chronic pulmonary disease


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • HIV negative
  • No active infection
  • No poorly controlled diabetes
  • No cerebral disorder
  • No other concurrent malignancy except adequately treated basal cell skin cancer or cervical intraepithelial neoplasia
  • No significant non-malignant disease
  • No psychiatric, addictive, or other disorder that would preclude study compliance


Biologic therapy:

  • Not specified


  • See Disease Characteristics
  • No other concurrent chemotherapy

Endocrine therapy:

  • Not specified


  • See Disease Characteristics


  • Not specified


  • At least 6 months since prior coronary angioplasty
  • No other concurrent investigational drugs
  • No concurrent non-steroidal anti-inflammatory drugs, salicylate, sulfonamide, trimethoprim, allopurinol, aminoglycoside, amoxicillin, or probenecid during high-dose methotrexate administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00025636

  Show 44 Study Locations
Sponsors and Collaborators
German Hodgkin's Lymphoma Study Group
European Organisation for Research and Treatment of Cancer - EORTC
EBMT Solid Tumors Working Party
Investigator: Andreas Engert, MD Medizinische Universitaetsklinik I at the University of Cologne
Investigator: J. W. Baars, MD, PhD The Netherlands Cancer Institute
Investigator: Norbert Schmitz, MD, PhD Asklepios Klinik St. Georg
  More Information Identifier: NCT00025636     History of Changes
Other Study ID Numbers: CDR0000068981  GHSG-HD-R2  EBMT-GHSG-HD-R2  EORTC-20011 
Study First Received: October 11, 2001
Last Updated: September 16, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent adult Hodgkin lymphoma

Additional relevant MeSH terms:
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on May 04, 2016